Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JL19001 in High Risk Non-Muscle Invasive Bladder Cancer
NCT07483970Phase 1Recruiting
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
- Start
- May 2026
- Primary completion
- Mar 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of JL19001 in non-muscle-invasive bladder cancer (NMIBC) (3 arms), sponsored by Jecho Biopharmaceuticals Co., Ltd. Primary endpoints: Dose-Limiting Toxicity at 21 days, Adverse Events at 3 years and 1 more. Started May 2026; status: recruiting.
02
Drugs
JL19001
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07483970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483970.